Ann: FDA Update for CONNEQT Companion App, page-11

No assumptions, the device IS fully dependent on the app IMO:

"The Agreement with Andon in conjunction with the ATCOR “Pulse” device significantly
expands the commercial market opportunity for CardieX into the home consumer health
device market, which is estimated to be worth $US2.5B annually (Source: Fortune Business
Insight).
When paired with ATCOR’s Arty™ app, the Device will provide fullremote patient monitoring
of a patient’s vital signs at home. The remote patient monitoring market is estimated to
reach $US43B by 2027 (Source: 2020 Research & Markets Report).
At launch, the device and will also be fully telehealth-enabled with video, chat, messaging,
customizable screens and full vital signs sharing features between clinician and patient when
paired with the Company’s Arty™ app. ATCOR Pulse will be the first blood pressure device
ever to feature customizable screens and vital signs modules when integrated with the
Company’s new Arty™ app."